Core Viewpoint - Chengdu Yuandong Biopharmaceutical Co., Ltd. has signed an agreement with an affiliated party to procure a production information system, aiming to enhance digital and intelligent management in the pharmaceutical industry [1][3]. Summary by Sections 1. Overview of the Related Transaction - The company’s wholly-owned subsidiary, Chengdu Shod Pharmaceutical Co., Ltd., plans to purchase a production information system from Beijing Qilijia Technology Co., Ltd. for a total amount of 2.2 million RMB, with a contract duration of three years [1][3][7]. 2. Basic Information of the Related Party - Beijing Qilijia Technology Co., Ltd. has a registered capital of 5 million RMB and was established on October 25, 2002. The company specializes in software development, technology consulting, and related services [2][5]. 3. Financial Data of the Related Party - As of June 30, 2025, Qilijia reported total assets of 1470.98 million RMB and total liabilities of 205.94 million RMB, with an owner's equity of 1265.04 million RMB. The company had a revenue of 392.14 million RMB in the first half of 2025 [5]. 4. Necessity and Impact of the Related Transaction - The transaction is essential for the company to implement digital and intelligent management in pharmaceutical production, aligning with the interests of the company and all shareholders. The pricing of the transaction is fair and does not harm the interests of minority shareholders [9][11]. 5. Approval Process for the Related Transaction - The independent directors and the board of supervisors have approved the transaction, confirming that it complies with the company's procurement management system and is based on fair market conditions [10][11].